BREYANZI disp perf 5.5 bis 322x10e6 CAR+ T-Zellen
7680674690016
CH-67469
L01XL08
07.16.4.
1 / 3
google
Details
- GTIN
- 7680674690016
- Pharmacode
- -
- Product number
- 6746901
- CPT
- -
- Packaging group
- 1 bis 4
- Unit
- Durchstechflasche(n)
- Composition
- Suspension: lisocabtagenum maraleucelum , enthält genetisch modifizierte Zellen (CD4+ oder CD8+ Komponente, Zieldosis 100x10e6 CAR+ T-Zellen in Zielverhältnis 1:1 von CD4+ und CD8+ Komponenten) 5.5 bis 322x10e6 CAR+ T-Zellen, CryoStor CS10, dextranum 40, dimethylis sulfoxidum, natrii chloridum, natrii gluconas, natrii acetas trihydricus, kalii chloridum, magnesii chloridum hexahydricum, aqua ad iniectabile, albumini humani solutio, N-acetyltryptophanum natricum, acidum caprylicum, ad praeparationem pro.
Articles (1)
Breyanzi, Suspension
suspension
1 bis 4
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
lisocabtagenum maraleucelum
|
- | Substance | Wirkstoff (Principe actif) |
|
CryoStor CS10
|
- | Substance | HIMDK |
|
dextranum 40
|
- | Substance | HNIDK |
|
dimethylis sulfoxidum
|
- | Substance | HNIDK |
|
natrii chloridum
|
- | Substance | HNIDK |
|
natrii gluconas
|
- | Substance | HNIDK |
|
natrii acetas trihydricus
|
- | Substance | HNIDK |
|
kalii chloridum
|
- | Substance | HNIDK |
|
magnesii chloridum hexahydricum
|
- | Substance | HNIDK |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
|
albumini humani solutio
|
- | Substance | HNIDK |
|
N-acetyltryptophanum natricum
|
- | Substance | HNIDK |
|
acidum caprylicum
|
- | Substance | HNIDK |
Authorization holder
Bristol-Myers Squibb SA
6312 Steinhausen
Authorization information
- Swissmedic authorization number
- 67469
- Drug name
- Breyanzi, Suspension
- Galenic form
- INFD
- ATC Code
- L01XL08
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 28/03/2022
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.4.
- Domain
- Human medicine
Packaging details
- Description (FR)
- BREYANZI disp perf 5.5 bis 322x10e6 CAR+ T-Zellen
- Description (DE)
- BREYANZI Inf Disp 5.5 bis 322x10e6 CAR+ T-Zellen
- Market launch
- 28/03/2022
- Narcotic (BTM)
- No
Application methods
IV